DF
EBS icon

Donoghue Forlines’s Emergent Biosolutions EBS Stock Holding History

Donoghue Forlines’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,562
Closed -$424K – 210
2021
Q1 		$424K Buy
4,562
+726
+19% +$74.4K 0.08% 192
2020
Q4 		$344K Buy
+3,836
New +$352K 0.07% 216

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Donoghue Forlines's EBS Position: Q2 2021 in Review

Donoghue Forlines sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 4,562 shares — an estimated $424K sold.

Donoghue Forlines first reported a position in EBS in Q4 2020 and held it in 2 quarters. The position peaked at $424K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Donoghue Forlines reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Donoghue Forlines sold 4,562 Emergent Biosolutions shares in Q2 2021, an estimated $424K.
  • Donoghue Forlines first reported a position in Emergent Biosolutions in Q4 2020 and held it in 2 quarters.
  • Donoghue Forlines's Emergent Biosolutions position peaked at $424K in Q1 2021.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Donoghue Forlines's 13F filing for Q2 2021, filed 16 Aug 2021.